Advancements in Endocrine Testing – Case Studies and Solutions for Clinical Trials

Diabetes is the 7th leading cause of death in the U.S. and affects over 350 million people worldwide, according to the World Health Organization. Likewise, it is estimated that one in six men will be diagnosed with prostate cancer in their lifetime- the second most common cancer in the world. It is therefore no surprise that drug developers are currently working on over 500 clinical trials for hormone or steroid driven diseases, such as prostate cancer, diabetes and other metabolic diseases – highly complex areas of clinical study.

Detection of very low levels of hormones and related molecules are an important facet of monitoring investigational agents that target these diseases and allows for a more informed understanding of drug response and optimization of dose, regimen and treatment during clinical development.

Through the integration of world-class specialty testing expertise and an extensive network of regional and central laboratories, LabCorp offers a comprehensive global solution for clinical trials involving endocrinology testing in diabetes, prostate cancer, and other hormone or steroid driven diseases. LabCorp offers cutting edge technology by harmonizing liquid chromatography and mass spectrometry technology that yields highly sensitive and specific assays at low level concentrations of hormones and steroids.

In this webinar, an overview of clinically relevant assays for ultrasensitive endocrine clinical trial testing services will be discussed by LabCorp scientists Dr. Walt Chandler, Head of R&D for Endocrine Sciences and Dr. Patrice Hugo, Senior Director of Global Scientific Affairs. Ongoing and future proprietary assays for diabetes, bone metabolism, thyroid and adrenal function, development and reproduction using age related reference ranges will also be highlighted in this presentation.

Speakers

Walt Chandler, PhD, Executive Director of Endocrine Sciences, LabCorp

Dr. Walt Chandler is the Executive Director of Endocrine Sciences, Esoterix Inc., a LabCorp endocrine testing laboratory with a staff of over 160 personnel. Walt oversees the development and validation of testing methods for various endocrinology disorders. Dr. Chandler completed his Ph.D. in biochemistry from the University of California, Los Angeles and has been a part of the Endocrine Sciences staff since its inception in 1972. He has also authored over 25 publications.

Message Presenter

Patrice Hugo, PhD, Chief Scientist, LabCorp Clinical Trials

Dr. Patrice Hugo, Chief Scientist at LabCorp Clinical Trials, has 20 years of biomarker experience. He obtained his Ph.D. at McGill University and completed 5 years of post-doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado. He was Principal Investigator at the Montreal Clinical Research Institute and worked in biotechs EVP R&D and Chief Scientific Officer. Dr. Hugo joined the Central lab industry as CSO of Clearstone Central Lab before its acquisition by LabCorp. He is author or co-author of over 80 scientific manuscripts.

Message Presenter